The company made the announcement after a new round of research results bolstered the case for the experimental medicine, ...

Apogee Enterprises has entered a definitive agreement to acquire Kalwall Companies from the Keller family for up to $115 million, adding a skylight manufacturer to its portfolio of architectural ...

Key Points Interested in Apogee Therapeutics Inc.? Here are five stocks we like better. Apogee Therapeutics plans to advance ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best high short interest stocks with highest upside potential. On May 27 ...

Apogee Therapeutics advances zumilokibart with a $1.3B Blackstone deal, eyes $82.97 value despite asset risks. Read why APGE ...

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in ...

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic d ...

Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following i ...

On May 31, 2026, the Moon reaches apogee, the point where it’s farthest from Earth in its orbit. This apogee has a very ...

One takeaway from the ongoing biotech IPO drought is that companies should have at least some clinical data to persuade investors to buy in. Apogee Therapeutics has no human data. In fact, the young ...

Great Point Partners increased its APGE position by 70,000 shares in the fourth quarter; the estimated transaction value was $4.41 million based on quarterly average prices. Meanwhile, the quarter-end ...

Apogee Therapeutics Inc. (NASDAQ:APGE) stock is experiencing a significant surge, trading almost 29% higher in premarket on Monday. This substantial increase in stock price follows the release of ...